Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin.

  title={Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin.},
  author={Jeffrey W. Taub and X Huang and Larry H. Matherly and M L Stout and S A Buck and Gita V. Massey and D L Becton and M N Chang and Howard J. Weinstein and Yaddanapudi Ravindranath},
  volume={94 4},
The high event-free survival rates of Down syndrome (DS) children with acute myeloid leukemia (AML) are due, in part, to increased in vitro sensitivity of DS myeloblasts to cytosine arabinoside (ara-C) and daunorubicin and the greater generation of ara-C triphosphate (ara-CTP) from ara-C compared with myeloblasts from non-DS patients (Taub et al, Blood 87:3395, 1996). This study further explores the molecular basis of chemotherapy sensitivity of DS AML patients by examining the expression of… 

Figures and Tables from this paper

The Role of Cytidine Deaminase and GATA1 Mutations in the Increased Cytosine Arabinoside Sensitivity of Down Syndrome Myeloblasts and Leukemia Cell Lines

Identification of the mechanisms of differential expression of genes encoding enzymes involved in ara-C metabolism between DS and non-DS myeloblasts may lead to improvements in AML therapy and the potential role of GATA1 in regulating CDA transcription and the CDAsf promoter acting as an enhancer is suggested.

Leukemia in Down Syndrome : A Model of in Vivo and in Vitro in CCRF-CEM Leukemia Cells-d-Arabinofuranosylcytosine β Sensitivity and Metabolism of 1-- Synthase cDNA Transfection Alters the β Cystathionine-Updated

Results suggest a posttranscriptional regulation of dCK in CBS-overexpressing cells that contributes to increased ara-C phosphorylation and drug activity.


It is concluded that fibroblasts derived from individuals affected with Down's syndrome are better protected from the damage induced by DNR than normal cells.

The Management of Neoplastic Disorders of Haematopoeisis in Children with Down's Syndrome

  • B. Lange
  • Medicine
    British journal of haematology
  • 2000
The current management strategy for these disorders, with few exceptions and considerable caution, is simple: in TMD, do nothing'; in AML, `do less'; and in ALL, ` do more'.

Down syndrome, drug metabolism and chromosome 21

Microarray technology should lead to the identification of additional gene targets linked to the treatment response of specific cytogenetic leukemia subgroups, including Down syndrome patients with megakaryocytic leukemia.

Hematological disorders in children with Down syndrome

In contrast to the excellent prognosis of ML-DS obtained likewise with low doses of chemotherapy, DS-ALL patients show worse outcomes than non-DS children, therefore advances and risk-stratified treatment adjustments are mandatory for this particular set of patients.

A Clinical Update on Employing Tocilizumab to Fight COVID-19

In this chapter, preference is given to Tocilizumab with the latest status of clinical research update available for SARS-CoV-2 infection.

Outcomes of patients with Down syndrome and acute leukemia

It is suggested that DS-ALL and DS-AML should be considered as independent diseases and treated according to specific protocols with therapy optimization per the minimal residual disease.



Méthylation des phospholipides dans les fibroblastes de patients atteints de trisomie 21.

The phospholipid methylation pathway appears to be a minor pathway, as compared to the choline pathway of phosphatidylcholine synthesis and thus does not allow the detection of an eventual disturbance of monocarbon metabolism in Down syndrome.

Cancer chemotherapy handbook

This book contains information on the biotechnology agents for cancer treatment and support and the use of new recombinant proteins.

Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood

This Compared autologous bone marrow transplantation with intensive consolidation chemotherapy as treatments for children with AML in first remission and induced remission with one course of daunorubicin, cytarabine, and thioguanine.

Treatment of childhood acute myeloid leukaemia.

Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498.

Compared with children without DS, children with DS had a superior event-free survival and remained superior even when compared with non-DS children less than 2 years of age with a white blood cell count less than 10 x 100,000/microL.

Genomic sequence and expression of a cloned human carbonyl reductase gene with daunorubicin reductase activity.

Transient expression of the genomic gene in COS7 cells using an expression vector containing an SV40 origin of replication resulted in a greater than 50-fold increase in both menadione reductase activity and daunorubicin reduct enzyme activity, suggesting that both activities are derived from the same enzyme.

The molecular genetics of Down syndrome.